Join the Portal
Contact Us
CTSA Pharmaceutical Assets Portal
The CTSA Pharmaceutical Assets Portal invites you to join in the effort to find new uses for discontinued drugs.
The Portal members are given an unprecedented opportunity to collaborate with Pfizer Indications Discovery Unit, a division of Pfizer vested with finding new uses for old drugs.
In addition to the compounds that you may be aware of from publically-available sources, Pfizer is also encouraging inquiries about the existence/availability of little known Pfizer compounds that target specific mechanisms in which you may have an interest. We call these "unknown" assets "Dream Compounds".
The ultimate goal is to leverage existing compounds to advance mechanistic understanding of human disease, resulting in novel treatments for patients. Integration of academic investigators into collaborative repositioning efforts with Pfizer would substantially increase the knowledge base and the pool of methodologies available for proof of concept studies. These matches will undoubtedly result in an increased number of approved drugs for new indications and considerable public benefit.
Membership in the Portal is free for CTSA researchers.
If you have any questions, please contact: Kate Marusina, Ph.D., MBA |
The Portal is sponsored by Clinical and Translational Sciences Award from NCRR,and by Pfizer, and supported by the efforts of: University of California in Davis |
Recent News
The Pharma Portal project is presented at the CHI Conference, Encouraging Development of Therapeutics for Neglected Diseases June 2010
Download the presentation
May 2010. Breaking News: The AP (5/18) reports, "Pfizer Inc. said Monday it will give Washington University $22.5 million and partner with its scientists to discover new uses for existing drug compounds." Pfizer also said it will provide the university "with information on more than 500 drugs and drug candidates," and it "has developed an online portal for university investigators to" review the company's data. Read the full article
Pharmascience is soliciting grant proposals for drug repositioning of brand or generic products and modified formulations, reformulation or new format of delivery.
Deadline is June 28, 2010
More information
The Portal in Nature Medicine, January 2010: Matchmaking service links up researchers to wallflower drugs
January 2010. European Molecular Biology Laboratory's European Bioinformatics Institute launches ChEMBL is a database of 500,000 bioactive compounds, their quantitative properties and bioactivities (binding constants, pharmacology and ADMET, etc). The data is abstracted and curated from the primary scientific literature and the data made available due to funding by the Wellcome Trust. You can search available compounds based on the target and view the detailed ChEBI Compound ID.
http://www.ebi.ac.uk/chembldb/index.php/target
CTSA Pharmaceutical Assest Portal is highlited on the NIH Forecast Report to the Office of the Secretary of Health and Human Services
The National Center for Research Resources along with the National Cancer Institute and the Clinical Center at the National Institutes of Health present:
CTSA Pharmaceutical Assets Portal: Matching Academia and Industry for Drug Repositioning
Friday, December 4, 2009
9:00 a.m. – noon
Lipsett Amphitheater, Building 10, NIH Campus, Bethesda, MD
View Agenda
CTSA Presents the Portal Project at the annual Drug Repositioning Summit in Boston, October 14, 2009
download PDF of the presentation
CTSA Pharma Portal in Proto Magazine, July 2009
Read about the Portal Project in the CTSA Newsletter, March 2,
2009